سوق اختبارات الدم الخفي في البراز في أمريكا الشمالية – اتجاهات الصناعة والتوقعات حتى عام 2030

Request for TOC طلب جدول المحتويات Speak to Analyst تحدث إلى المحلل Buy Now اشتري الآن Inquire Before Buying استفسر قبل Free Sample Report تقرير عينة مجاني

سوق اختبارات الدم الخفي في البراز في أمريكا الشمالية – اتجاهات الصناعة والتوقعات حتى عام 2030

  • Pharmaceutical
  • Published Report
  • Feb 2023
  • North America
  • 350 الصفحات
  • عدد الجداول: 183
  • عدد الأرقام: 35

North America Fecal Occult Blood Tests Market

حجم السوق بالمليار دولار أمريكي

CAGR :  % Diagram

Diagram فترة التنبؤ
2024 –2030
Diagram حجم السوق (السنة الأساسية)
مليون دولار أمريكي
Diagram حجم السوق (سنة التنبؤ)
USD 1,019.00
Diagram CAGR
%
Diagram Major Markets Players
  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5

>سوق اختبارات الدم الخفي في البراز في أمريكا الشمالية، حسب نوع الاختبار (مجموعات اختبار التدفق الجانبي المناعي، مجموعات اختبار التراص المناعي، مجموعات اختبار ELISA المناعي، اختبار البراز Guaiac FOB، وسادة أو أنسجة الكاشف القابلة للتصريف، وغيرها)، التطبيق (فحص سرطان القولون والمستقيم، القلق بشأن النزيف المعوي، الاورام الحميدة، داء الرتوج، القرحة، البواسير، التهاب القولون، فقر الدم وغيرها)، المستخدم النهائي (المختبرات التشخيصية والمستشفيات والعيادات المتخصصة وغيرها)، قناة التوزيع (المبيعات المباشرة، مبيعات التجزئة، التجارة الإلكترونية وغيرها)، اتجاهات الصناعة والتوقعات حتى عام 2030.

سوق اختبارات الدم الخفي في البراز في أمريكا الشمالية

تحليل حجم سوق اختبارات الدم الخفي في البراز في أمريكا الشمالية

أحد العوامل الأساسية التي تدفع نمو سوق اختبارات الدم الخفي في البراز هو ارتفاع حالات الإصابة بسرطان القولون والمستقيم في أمريكا الشمالية. يؤدي البحث المستمر في التجارب السريرية التي تجريها العديد من الشركات لتحسين التشخيص إلى توسع السوق. يتأثر السوق أيضًا بتطوير الاختبارات المعملية المباشرة للمستهلك وسهولة توفر أجهزة اختبار المناعة الخفية في البراز في المتاجر عبر الإنترنت.

سوق اختبارات الدم الخفي في البراز في أمريكا الشمالية

سوق اختبارات الدم الخفي في البراز في أمريكا الشمالية

 من المتوقع أن يحقق سوق اختبارات الدم الخفي في البراز في أمريكا الشمالية نموًا في السوق في الفترة المتوقعة من 2023 إلى 2030. تحلل Data Bridge Market Research أن السوق ينمو بمعدل نمو سنوي مركب قدره 5.9٪ في الفترة المتوقعة من 2023 إلى 2030 ومن المتوقع أن يصل إلى 1،019.00 مليون دولار أمريكي بحلول عام 2030.

تقرير القياس

تفاصيل

فترة التنبؤ

2023 إلى 2030

سنة الأساس

2022

سنوات تاريخية

2021 (قابلة للتخصيص حتى 2015-2020)

وحدات كمية

الإيرادات بالملايين من الدولارات الأمريكية

القطاعات المغطاة

حسب نوع الاختبار (مجموعات اختبار التدفق الجانبي المناعي، مجموعات اختبار التراص المناعي، مجموعات اختبار الإليزا المناعي، اختبار البراز الغاياك، وسادات أو أنسجة الكاشف القابلة للتصريف، وغيرها)، والتطبيق (فحص سرطان القولون والمستقيم، والقلق بشأن النزيف المعوي، والأورام الحميدة، والتهاب الرتوج، والقرحة، والبواسير، والتهاب القولون، وفقر الدم، وغيرها)، والمستخدم النهائي (المختبرات التشخيصية، والمستشفيات، والعيادات المتخصصة، وغيرها)، وقناة التوزيع (المبيعات المباشرة، ومبيعات التجزئة، والتجارة الإلكترونية، وغيرها)

الدول المغطاة

الولايات المتحدة وكندا والمكسيك

الجهات الفاعلة في السوق المشمولة

Biopanda Reagents Ltd، وHUMASIS.COM، وCTK Biotech, Inc.، وBiohit Oyj، وCERTEST BIOTEC، وAlfa Scientific Designs, Inc.، وCenogenics Corporation، وJant Pharmacal Corporation.، وQuidel Corporation، وWondfo.، وSiemens Healthcare GmbH وغيرها

تعريف السوق

اختبار الدم الخفي في البراز (FOBT) هو اختبار فحص تشخيصي يتم إجراؤه لتحليل الدم الخفي (الخفي) في عينات البراز. يُعرف اختبار الدم الخفي في البراز أيضًا باسم الدم الخفي في البراز، واختبار المناعة FOBT، واختبار الدم الخفي، واختبار IFOBT واختبار لطاخة الغاياك بشكل عام. يُستخدم الاختبار بشكل أساسي لفحص سرطان القولون وتحليل الأسباب المحتملة لفقر الدم غير المبرر.

ديناميكيات سوق اختبارات الدم الخفي في البراز

يتناول هذا القسم فهم محركات السوق والفرص والقيود والتحديات. وسيتم مناقشة كل هذا بالتفصيل أدناه:

السائقين

  • Rising Cases Of Colorectal Cancer in North America

Colorectal cancer is a disease of the colon or rectum, which are parts of the digestive system. Unlike most cancers, colorectal cancer is often preventable with screening & can be treated when detected early. Most cases of colorectal cancer occur in people ages 45 & older. The disease is increasingly affecting younger people due to unhygienic lifestyles & smoking habits. Colorectal cancers may develop without symptoms. The common symptoms may include blood in or on the stool, persistent unusual bowel movements like constipation or diarrhea, stomach pain, aches or cramps that last longer and losing weight for no reason.

Most colorectal cancers start as abnormal tissue growth, called a polyp, inside the colon or rectum. Doctors can detect polyps with the help of screening tests & can remove them from developing into colorectal cancer. Even if it spreads into nearby lymph nodes, chemotherapy & surgical treatments are effective ways to treat colorectal cancer. Research is going on to learn more about this disease and provide more hope to people with all stages of colorectal cancer.

  • Direct-to-consumer Laboratory Testing

Direct-to-consumer laboratory testing is an effective way for users where they can order their corresponding laboratory tests directly from a lab without any healthcare providers. Nowadays, the healthcare industry is shifting towards direct-to-consumer laboratory testing from physician-based lab testing & hence the demand has increased drastically. Most of the patients are focusing on direct-to-consumer based laboratory tests without going through a lengthy in-clinic process, which is fueling the growth of the fecal occult blood tests market.

For the identification of previously unknown medical disorders, the test results are used. The advancements in the field of direct-to-consumer laboratory testing have become crucial to increase patient engagement for better monitoring & screening of existing health conditions. Hence, it is very important for laboratory professionals to upgrade the devices & instruments used in testing laboratories.

  • Easy Availability Of Fecal Occult Immunological Test Devices In Online Stores

A fecal occult blood test (FOBT) generally focuses on a stool sample to check for blood. The presence of blood in stool refers that there is bleeding in the digestive tract. The bleeding can be caused by a variety of conditions like Polyps (abnormal growths on the lining of the colon or rectum), Hemorrhoids (swollen veins in the anus or rectum), Diverticulosis (a condition with small pouches in the inside wall of the colon), Ulcers (sores in the lining of the digestive tract), Colitis (a type of inflammatory bowel disease) and Colorectal cancer.

There are a huge number of fecal occult immunological test devices available in the market, and people can buy the kits & devices from various online sites. Hence, it can be a driving factor for the growth of the fecal occult blood tests market.

Opportunities

  • Increase in screening procedures

Most government agencies and scientific societies recommend cervical, breast, and colorectal screening because of the burden of these cancers, the availability of screening tests, and the proven efficacy of screening in reducing mortality, as well as incidence, for cervical and colorectal cancers.

The European Community recommends the implementation of population-based screening programs for colorectal cancers. This recommendation is supported by many observational studies showing that organized programs effectively reduce mortality and control the inappropriate use of screening tests.

  • Rising technical advancements

A blood test has always been a technology- and data-dependent field. As data and technology potentially revolutionized diagnostic services and had positioned to partner with patients, families, practitioners, researchers, industry leaders, policymakers, and administrators to ensure that humanistic, high-value, ever-improving precise diagnosis remains the central goal for the future of blood test diagnosis.

The use of fecal occult blood testing has expanded to several indications, even though its primary use is for evaluating an occult source of GI blood loss and for home-based kits in colorectal carcinoma screening. One of the most common clinical uses for the hemoccult is for checking a stool specimen for occult bleeding prior to anticoagulation.

Restraints/Challenges

  • Change In Consumer Preference Towards Cost-Effective Alternatives

The fecal occult blood test products bear a high cost and usually cannot be afforded by everyone in general. As technology is getting more advanced day by day & there are a number of test alternatives available in the market. Hence, people prefer cost-effective alternatives for fecal occult blood tests. There are various screening programs that often target people with apparently healthy conditions & the number of people using screening services is usually higher than the true number of patients. The FOBT has advantages over colonoscopy in terms of being less costly and easy to perform.

As most of the fecal occult blood test alternatives are available in the market. Hence, people prefer substitutes with lesser cost & more accurate results. Hence, the change in consumer preference toward cost-effective alternatives may restrain the market growth in the forecast period.

  • Low efficiency

The fecal occult blood test is not always accurate and could show a negative test result when cancer is present and have a false-negative result if cancer or polyps do not bleed.

The test could show a positive result when the person has no cancer (false-positive result) or have bleeding from other sources, such as a stomach ulcer, hemorrhoid, or even blood swallowed from the mouth or nose.

Post-COVID-19 Impact on the Fecal Occult Blood Tests Market

The COVID-19 pandemic had a great impact on the fecal occult blood test industries. Trade groups in colorectal cancer and gastrointestinal bleeding diagnostic products sector claim that the North America supply chain for diagnostic products has been significantly damaged, impacting end-user consumption of the fecal occult blood tests market. Sales of test products in the first quarter of 2020 were significantly delayed due to logistical and transportation issues. On the demand side, the market is increasing as people have to get diagnosed after the lockdown scenario. The situation needs to be taken into consideration, and emergency diagnostics need to be done. Furthermore, on the supply side, the growth of the market is on a negative scale. This is due to the lockdown situations in many countries manufacturing diagnostic, operating and cancer care and fecal occult blood test instruments.

Recent Developments

  • In November 2022, Eiken Chemical Co, Ltd. had launched the fully automated fecal immunochemical test/ Faecal Calprotectin Analyzer “OC-SENSOR Ceres.” This has helped the company to establish its product North Americaly
  • In January 2022, Boditech Med Inc. announced that it had signed a USD19.2 Million supply agreement with A. Menarini Diagnostics to accelerate its product portfolio. This helps the organization in generating revenue

North America Fecal Occult Blood Tests Market Scope

The North America fecal occult blood tests market is segmented into four notable segments based on test type, application, end user and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to make strategic decisions to identify core market applications.

Test Type

  • Lateral Flow Immuno-FOB Test Kits
  • Immuno-FOB Agglutination Test Kits
  • Immuno-FOB ELISA Test Kits
  • Guaiac FOB Stool Tests
  • Flushable Reagent Pad Or Tissue
  • Others

On the basis of test type, the North America fecal occult blood tests market is segmented into lateral flow immuno-FOB test kits, immuno-FOB agglutination test kits, immuno-FOB ELISA test kits, guaiac FOB stool tests, flushable reagent pad or tissue, and others.

Application

  • Colorectal Cancer Screening
  • Concern For Gastrointestinal Bleeding
  • Polyps
  • Diverticulosis
  • Ulcers
  • Haemorrhoids
  • Colitis
  • Anemia
  • Others

On the basis of application, the North America fecal occult blood tests market is segmented into Colorectal Cancer Screening, Concern for gastrointestinal bleeding, Polyps, Diverticulosis, Ulcers, Haemorrhoids, Colitis, Anemia, and others.

End User

  • Diagnostic Laboratories
  • Hospitals
  • Specialty Clinics
  • Others

على أساس المستخدم النهائي، يتم تقسيم سوق اختبارات الدم الخفي في البراز في أمريكا الشمالية إلى مختبرات التشخيص والمستشفيات والعيادات المتخصصة وغيرها.

قناة التوزيع

  • العطاء المباشر
  • مبيعات التجزئة
  • التجارة الإلكترونية
  • آحرون

على أساس قناة التوزيع، يتم تقسيم سوق اختبارات الدم الخفي في البراز في أمريكا الشمالية إلى العطاءات المباشرة، ومبيعات التجزئة، والتجارة الإلكترونية، وغيرها.

سوق اختبارات الدم الخفي في البراز

تحليل/رؤى إقليمية لسوق اختبارات الدم الخفي في البراز

يتم تحليل سوق اختبارات الدم الخفي في البراز، ويتم توفير رؤى حجم السوق والاتجاهات حسب البلد ونوع الاختبار والتطبيق والمستخدم النهائي وقناة التوزيع، كما هو مذكور أعلاه.

 يشتمل سوق اختبارات الدم الخفي في البراز في أمريكا الشمالية على دول الولايات المتحدة وكندا والمكسيك.

من المتوقع أن تهيمن الولايات المتحدة على سوق اختبارات الدم الخفي في البراز في أمريكا الشمالية بسبب الميل المتزايد نحو التشخيصات في نقطة الرعاية. ومن المتوقع أيضًا أن يؤدي زيادة الطلب على منتجات اختبار الدم الخفي في البراز وزيادة أنشطة البحث والتطوير في الصناعة إلى دفع السوق في الفترة المتوقعة.

كما يوفر قسم الدولة في التقرير عوامل التأثير الفردية على السوق والتغييرات في اللوائح في السوق والتي تؤثر على الاتجاهات الحالية والمستقبلية للسوق. تعد نقاط البيانات، مثل المبيعات الجديدة والاستبدالية، والتركيبة السكانية للدولة، وعلم الأوبئة المرضية، ورسوم الاستيراد والتصدير، من بين المؤشرات الرئيسية المستخدمة للتنبؤ بسيناريو السوق للدول الفردية. بالإضافة إلى ذلك، يتم النظر في وجود وتوافر العلامات التجارية في أمريكا الشمالية والتحديات التي تواجهها بسبب المنافسة الشديدة من العلامات التجارية المحلية والمحلية، وتأثير قنوات المبيعات أثناء تقديم تحليل تنبؤي لبيانات الدولة.

تحليل المنافسة وحصة سوق اختبارات الدم الخفي في البراز في أمريكا الشمالية

يقدم المشهد التنافسي لسوق اختبارات الدم الخفي في البراز تفاصيل عن المنافسين. تتضمن التفاصيل نظرة عامة على الشركة، والبيانات المالية للشركة، والإيرادات المتولدة، وإمكانات السوق، والاستثمار في البحث والتطوير، ومبادرات السوق الجديدة، والحضور في أمريكا الشمالية، ومواقع الإنتاج والمرافق، والقدرات الإنتاجية، ونقاط القوة والضعف للشركة، وإطلاق المنتج، وعرض المنتج ونطاقه، وهيمنة التطبيق. ترتبط نقاط البيانات المذكورة أعلاه فقط بتركيز الشركات على سوق اختبارات الدم الخفي في البراز في أمريكا الشمالية.

بعض اللاعبين الرئيسيين العاملين في هذا السوق هم Biopanda Reagents Ltd، HUMASIS.COM، CTK Biotech، Inc.، Biohit Oyj، CERTEST BIOTEC، Alfa Scientific Designs، Inc.، Cenogenics Corporation، و Jant Pharmacal Corporation.، Quidel Corporation، Wondfo.، Siemens Healthcare GmbH وغيرها.


SKU-

احصل على إمكانية الوصول عبر الإنترنت إلى التقرير الخاص بأول سحابة استخبارات سوقية في العالم

  • لوحة معلومات تحليل البيانات التفاعلية
  • لوحة معلومات تحليل الشركة للفرص ذات إمكانات النمو العالية
  • إمكانية وصول محلل الأبحاث للتخصيص والاستعلامات
  • تحليل المنافسين باستخدام لوحة معلومات تفاعلية
  • آخر الأخبار والتحديثات وتحليل الاتجاهات
  • استغل قوة تحليل المعايير لتتبع المنافسين بشكل شامل
طلب التجريبي

Table of Content

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF THE NORTH AMERICA FECAL OCCULT BLOOD TESTS MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATIONS

1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 DBMR TRIPOD DATA VALIDATION MODEL

2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.6 MULTIVARIATE MODELLING

2.7 PRODUCT TYPE SEGMENT LIFELINE CURVE

2.8 MARKET APPLICATION COVERAGE GRID

2.9 DBMR MARKET POSITION GRID

2.1 VENDOR SHARE ANALYSIS

2.11 SECONDARY SOURCES

2.12 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTEL ANALYSIS

4.2 PORTER'S 5 FORCES

5 INDUSTRY INSIGHTS

6 REGULATORY FRAMEWORK

6.1 REGULATORY SCENARIO BY U.S. FDA

6.2 REGULATORY SCENARIO IN U.S.

6.3 REGULATORY SCENARIO IN EUROPE

6.4 REGULATORY SCENARIO IN CANADA

6.5 REGULATORY SCENARIO IN AUSTRALIA

7 MARKET OVERVIEW

7.1 DRIVERS

7.1.1 RISING CASES OF COLORECTAL CANCER NORTH AMERICALY

7.1.2 DEVELOPMENT OF DIRECT-TO-CONSUMER LABORATORY TESTING

7.1.3 EASY AVAILABILITY OF FECAL OCCULT IMMUNOLOGICAL TEST DEVICES IN ONLINE STORES

7.1.4 INCREASING INCLINATION TOWARDS POINT-OF-CARE DIAGNOSTICS

7.2 RESTRAINTS

7.2.1 CHANGE IN CONSUMER PREFERENCE TOWARDS COST-EFFECTIVE ALTERNATIVES

7.2.2 LOW AWARENESS ABOUT FECAL OCCULT BLOOD TESTS IN UNDEVELOPED COUNTRIES

7.3 OPPORTUNITIES

7.3.1 INCREASE IN SCREENING PROCEDURES

7.3.2 RISING TECHNICAL ADVANCEMENTS

7.3.3 STRATEGIC INITIATIVES

7.4 CHALLENGES

7.4.1 LACK OF SKILLED PROFESSIONALS

7.4.2 LOW EFFICIENCY

8 NORTH AMERICA FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE

8.1 OVERVIEW

8.2 LATERAL FLOW IMMUNO-FOB TEST KITS

8.3 IMMUNO-FOB AGGLUTINATION TEST KITS

8.4 IMMUNO-FOB ELISA TEST KITS

8.5 GUAIAC FOB STOOL TEST

8.5.1 KITS

8.5.1.1 GUAIAC SLIDES

8.5.1.1.1 25 PACKAGE

8.5.1.1.2 20 PACKAGE

8.5.1.1.3 OTHERS

8.5.1.2 ALPHA GUAIACONIC ACID (GUAIAC) IMPREGNATED PAPER

8.5.1.2.1 SENSITIVITY IS 50NG/ML

8.5.1.2.1.1 25 PACKAGE

8.5.1.2.1.2 20 PACKAGE

8.5.1.2.1.3 OTHERS

8.5.1.2.2 SENSITIVITY IS 75NG/ML

8.5.1.2.2.1 25 PACKAGE

8.5.1.2.2.2 20 PACKAGE

8.5.1.2.2.3 OTHERS

8.5.1.2.3 OTHERS

8.5.1.3 OTHERS

8.5.2 REAGENTS

8.5.2.1 HYDROGEN PEROXIDE

8.5.2.2 OTHERS

8.6 FLUSHABLE REAGENT PAD OR TISSUE

8.7 OTHERS

9 NORTH AMERICA FECAL OCCULT BLOOD TESTS MARKET, BY APPLICATION

9.1 OVERVIEW

9.2 COLORECTAL CANCER SCREENING

9.2.1 LATERAL FLOW IMMUNO-FOB TEST KITS

9.2.2 IMMUNO-FOB AGGLUTINATION TEST KITS

9.2.3 IMMUNO-FOB ELISA TEST KITS

9.2.4 GUAIAC FOB STOOL TEST

9.2.5 FLUSHABLE REAGENT PAD OR TISSUE

9.2.6 OTHERS

9.3 CONCERN FOR GASTROINTESTINAL BLEEDING

9.3.1 LATERAL FLOW IMMUNO-FOB TEST KITS

9.3.2 IMMUNO-FOB AGGLUTINATION TEST KITS

9.3.3 IMMUNO-FOB ELISA TEST KITS

9.3.4 GUAIAC FOB STOOL TEST

9.3.5 FLUSHABLE REAGENT PAD OR TISSUE

9.3.6 OTHERS

9.4 POLYPS

9.4.1 LATERAL FLOW IMMUNO-FOB TEST KITS

9.4.2 IMMUNO-FOB AGGLUTINATION TEST KITS

9.4.3 IMMUNO-FOB ELISA TEST KITS

9.4.4 GUAIAC FOB STOOL TEST

9.4.5 FLUSHABLE REAGENT PAD OR TISSUE

9.4.6 OTHERS

9.5 DIVERTICULOSIS

9.5.1 LATERAL FLOW IMMUNO-FOB TEST KITS

9.5.2 IMMUNO-FOB AGGLUTINATION TEST KITS

9.5.3 IMMUNO-FOB ELISA TEST KITS

9.5.4 GUAIAC FOB STOOL TEST

9.5.5 FLUSHABLE REAGENT PAD OR TISSUE

9.5.6 OTHERS

9.6 ULCERS

9.6.1 LATERAL FLOW IMMUNO-FOB TEST KITS

9.6.2 IMMUNO-FOB AGGLUTINATION TEST KITS

9.6.3 IMMUNO-FOB ELISA TEST KITS

9.6.4 GUAIAC FOB STOOL TEST

9.6.5 FLUSHABLE REAGENT PAD OR TISSUE

9.6.6 OTHERS

9.7 HAEMORRHOIDS

9.7.1 LATERAL FLOW IMMUNO-FOB TEST KITS

9.7.2 IMMUNO-FOB AGGLUTINATION TEST KITS

9.7.3 IMMUNO-FOB ELISA TEST KITS

9.7.4 GUAIAC FOB STOOL TEST

9.7.5 FLUSHABLE REAGENT PAD OR TISSUE

9.7.6 OTHERS

9.8 COLITIS

9.8.1 LATERAL FLOW IMMUNO-FOB TEST KITS

9.8.2 IMMUNO-FOB AGGLUTINATION TEST KITS

9.8.3 IMMUNO-FOB ELISA TEST KITS

9.8.4 GUAIAC FOB STOOL TEST

9.8.5 FLUSHABLE REAGENT PAD OR TISSUE

9.8.6 OTHERS

9.9 ANEMIA

9.9.1 LATERAL FLOW IMMUNO-FOB TEST KITS

9.9.2 IMMUNO-FOB AGGLUTINATION TEST KITS

9.9.3 IMMUNO-FOB ELISA TEST KITS

9.9.4 GUAIAC FOB STOOL TEST

9.9.5 FLUSHABLE REAGENT PAD OR TISSUE

9.9.6 OTHERS

9.1 OTHERS

10 NORTH AMERICA FECAL OCCULT BLOOD TESTS MARKET, BY END USER

10.1 OVERVIEW

10.2 DIAGNOSTIC LABORATORIES

10.3 HOSPITALS

10.4 SPECIALITY CLINICS

10.5 OTHERS

11 NORTH AMERICA FECAL OCCULT BLOOD TESTS MARKET, BY DISTRIBUTION CHANNEL

11.1 OVERVIEW

11.2 DIRECT TENDER

11.3 RETAIL SALE

11.4 E-COMMERCE

11.5 OTHERS

12 NORTH AMERICA FECAL OCCULT BLOOD TESTS MARKET, BY REGION

12.1 NORTH AMERICA

12.1.1 U.S.

12.1.2 CANADA

12.1.3 MEXICO

13 NORTH AMERICA FECAL OCCULT BLOOD TESTS MARKET: COMPANY LANDSCAPE

13.1 COMPANY SHARE ANALYSIS: NORTH AMERICA

14 SWOT ANALYSIS

15 COMPANY PROFILE

15.1 QUIDEL CORPORATION

15.1.1 COMPANY SNAPSHOT

15.1.2 REVENUE ANALYSIS

15.1.3 COMPANY SHARE ANALYSIS

15.1.4 PRODUCT PORTFOLIO

15.1.5 RECENT DEVELOPMENT

15.2 WONDFO.

15.2.1 COMPANY SNAPSHOT

15.2.2 COMPANY SHARE ANALYSIS

15.2.3 PRODUCT PORTFOLIO

15.2.4 RECENT DEVELOPMENT

15.3 SIEMENS HEALTHCARE GMBH

15.3.1 COMPANY SNAPSHOT

15.3.2 REVENUE ANALYSIS

15.3.3 COMPANY SHARE ANALYSIS

15.3.4 RODUCT PORTFOLIO

15.3.5 RECENT DEVELOPMENT

15.4 EIKEN CHEMICAL CO., LTD.

15.4.1 COMPANY SNAPSHOT

15.4.2 REVENUE ANALYSIS

15.4.3 COMPANY SHARE ANALYSIS

15.4.4 PRODUCT PORTFOLIO

15.4.5 RECENT DEVELOPMENT

15.5 BIOHIT OYJ

15.5.1 COMPANY SNAPSHOT

15.5.2 REVENUE ANALYSIS

15.5.3 COMPANY SHARE ANALYSIS

15.5.4 PRODUCT PORTFOLIO

15.5.5 RECENT DEVELOPMENT

15.6 ACCUBIOTECH CO LTD

15.6.1 COMPANY SNAPSHOT

15.6.2 PRODUCT PORTFOLIO

15.6.3 RECENT DEVELOPMENT

15.7 ACCUQUIK TEST KITS

15.7.1 COMPANY SNAPSHOT

15.7.2 PRODUCT PORTFOLIO

15.7.3 RECENT DEVELOPMENT

15.8 AIDIAN

15.8.1 COMPANY PROFILE

15.8.2 PRODUCT PORTFOLIO

15.8.3 RECENT DEVELOPMENT

15.9 ALFA SCIENTIFIC DESIGNS, INC.

15.9.1 COMPANY SNAPSHOT

15.9.2 PRODUCT PORTFOLIO

15.9.3 RECENT DEVELOPMENT

15.1 APACOR LIMITED

15.10.1 COMPANY SNAPSHOT

15.10.2 PRODUCT PORTFOLIO

15.10.3 RECENT DEVELOPMENT

15.11 BIOPANDA REAGENTS LTD

15.11.1 COMPANY SNAPSHOT

15.11.2 PRODUCT PORTFOLIO

15.11.3 RECENT DEVELOPMENT

15.12 BODITECH MED INC.

15.12.1 COMPANY SNAPSHOT

15.12.2 PRODUCT PORTFOLIO

15.12.3 RECENT DEVELOPMENT

15.13 CENOGENICS CORPORATION

15.13.1 COMPANY SNAPSHOT

15.13.2 PRODUCT PORTFOLIO

15.13.3 RECENT DEVELOPMENT

15.14 CERTEST BIOTEC.

15.14.1 COMPANY SNAPSHOT

15.14.2 PRODUCT PORTFOLIO

15.14.3 RECENT DEVELOPMENT

15.15 CTK BIOTECH, INC.

15.15.1 COMPANY SNAPSHOT

15.15.2 PRODUCT PORTFOLIO

15.15.3 RECENT DEVELOPMENT

15.16 EDP BIOTECH

15.16.1 COMPANY SNAPSHOT

15.16.2 PRODUCT PORTFOLIO

15.16.3 1.16.3 RECENT DEVELOPMENT

15.17 EPITOPE DIAGNOSTICS, INC.

15.17.1 COMPANY SNAPSHOT

15.17.2 PRODUCT PORTFOLIO

15.17.3 RECENT DEVELOPMENT

15.18 EUROLYSER DIAGNOSTICA GMBH

15.18.1 COMPANY SNAPSHOT

15.18.2 PRODUCT PORTFOLIO

15.18.3 RECENT DEVELOPMENT

15.19 FIRSTEP

15.19.1 COMPANY SNAPSHOT

15.19.2 PRODUCT PORTFOLIO

15.19.3 RECENT DEVELOPMENT

15.2 HANGZHOU CLONGENE BIOTECH CO., LTD

15.20.1 COMPANY SNAPSHOT

15.20.2 PRODUCT PORTFOLIO

15.20.3 RECENT DEVELOPMENT

15.21 HUMASIS.COM

15.21.1 COMPANY SNAPSHOT

15.21.2 PRODUCT PORTFOLIO

15.21.3 RECENT DEVELOPMENT

15.22 JANT PHARMACAL CORPORATION

15.22.1 COMPANY SNAPSHOT

15.22.2 PRODUCT PORTFOLIO

15.22.3 RECENT DEVELOPMENT

15.23 PRIMA LAB SA

15.23.1 COMPANY SNAPSHOT

15.23.2 PRODUCT PORTFOLIO

15.23.3 RECENT DEVELOPMENT

15.24 ULTI MED PRODUCTS (DEUTSCHLAND) GMBH

15.24.1 COMPANY SNAPSHOT

15.24.2 PRODUCT PORTFOLIO

15.24.3 RECENT DEVELOPMENT

16 QUESTIONNAIRE

17 RELATED REPORTS

List of Table

TABLE 1 NORTH AMERICA FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 2 NORTH AMERICA LATERAL FLOW IMMUNO-FOB TEST KITS IN FECAL OCCULT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 3 NORTH AMERICA IMMUNO-FOB AGGLUTINATION TEST KITS IN FECAL OCCULT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 4 NORTH AMERICA IMMUNO-FOB ELISA TEST KITS IN FECAL OCCULT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 5 NORTH AMERICA GUAIAC FOB STOOL TEST IN FECAL OCCULT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 6 NORTH AMERICA GUAIAC FOB STOOL TEST IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 7 NORTH AMERICA KITS IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 8 NORTH AMERICA GUAIAC SLIDES IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 9 NORTH AMERICA ALPHA GUAIACONIC ACID (GUAIAC) IMPREGNATED PAPER IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 10 NORTH AMERICA SENSITIVITY IS 50NG/ML IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 11 NORTH AMERICA SENSITIVITY IS 75NG/ML IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 12 NORTH AMERICA REAGENTS IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 13 NORTH AMERICA FLUSHABLE REAGENT PAD OR TISSUE IN FECAL OCCULT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 14 NORTH AMERICA OTHERS IN FECAL OCCULT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 15 NORTH AMERICA FECAL OCCULT BLOOD TESTS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 16 NORTH AMERICA COLORECTAL CANCER SCREENING IN FECAL OCCULT BLOOD TESTS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 17 NORTH AMERICA COLORECTAL CANCER SCREENING IN FECAL OCCULT BLOOD TESTS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 18 NORTH AMERICA CONCERN FOR GASTROINTESTINAL BLEEDING IN FECAL OCCULT BLOOD TESTS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 19 NORTH AMERICA CONCERN FOR GASTROINTESTINAL BLEEDING IN FECAL OCCULT BLOOD TESTS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 20 NORTH AMERICA POYLPS IN FECAL OCCULT BLOOD TESTS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 21 NORTH AMERICA POLYPS IN FECAL OCCULT BLOOD TESTS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 22 NORTH AMERICA DIVERTICULOSIS IN FECAL OCCULT BLOOD TESTS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 23 NORTH AMERICA DIVERTICULOSIS IN FECAL OCCULT BLOOD TESTS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 24 NORTH AMERICA ULCERS IN FECAL OCCULT BLOOD TESTS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 25 NORTH AMERICA ULCERS IN FECAL OCCULT BLOOD TESTS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 26 NORTH AMERICA HAEMORRHOIDS IN FECAL OCCULT BLOOD TESTS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 27 NORTH AMERICA HEMORRHOIDS IN FECAL OCCULT BLOOD TESTS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 28 NORTH AMERICA COLITIS IN FECAL OCCULT BLOOD TESTS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 29 NORTH AMERICA COLITIS IN FECAL OCCULT BLOOD TESTS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 30 NORTH AMERICA ANEMIA IN FECAL OCCULT BLOOD TESTS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 31 NORTH AMERICA ANEMIA IN FECAL OCCULT BLOOD TESTS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 32 NORTH AMERICA OTHERS IN FECAL OCCULT BLOOD TESTS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 33 NORTH AMERICA FECAL OCCULT BLOOD TESTS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 34 NORTH AMERICA DIAGNOSTIC LABORATORIES IN FECAL OCCULT BLOOD TESTS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 35 NORTH AMERICA HOSPITALS IN FECAL OCCULT BLOOD TESTS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 36 NORTH AMERICA SPECIALITY CLINICS IN FECAL OCCULT BLOOD TESTS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 37 NORTH AMERICA OTHERS IN FECAL OCCULT BLOOD TESTS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 38 NORTH AMERICA FECAL OCCULT BLOOD TESTS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 39 NORTH AMERICA DIRECT TENDER IN FECAL OCCULT BLOOD TESTS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 40 NORTH AMERICA RETAIL SALE IN FECAL OCCULT BLOOD TESTS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 41 NORTH AMERICA RETAIL SALE IN FECAL OCCULT BLOOD TESTS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 42 NORTH AMERICA OTHERS IN FECAL OCCULT BLOOD TESTS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 43 NORTH AMERICA FECAL OCCULT BLOOD TESTS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)

TABLE 44 NORTH AMERICA FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 45 NORTH AMERICA FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (UNIT)

TABLE 46 NORTH AMERICA FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (ASP)

TABLE 47 NORTH AMERICA GUAIAC FOB STOOL TEST IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 48 NORTH AMERICA GUAIAC FOB STOOL TEST IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (UNIT)

TABLE 49 NORTH AMERICA GUAIAC FOB STOOL TEST IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (ASP)

TABLE 50 NORTH AMERICA KITS IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 51 NORTH AMERICA KITS IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (UNIT)

TABLE 52 NORTH AMERICA KITS IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (ASP)

TABLE 53 NORTH AMERICA GUAIAC SLIDES IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 54 NORTH AMERICA GUAIAC SLIDES IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (UNIT)

TABLE 55 NORTH AMERICA GUAIAC SLIDES IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (ASP)

TABLE 56 NORTH AMERICA ALPHA GUAIACONIC ACID (GUAIAC) IMPREGNATED PAPER IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 57 NORTH AMERICA ALPHA GUAIACONIC ACID (GUAIAC) IMPREGNATED PAPER IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (UNIT)

TABLE 58 NORTH AMERICA ALPHA GUAIACONIC ACID (GUAIAC) IMPREGNATED PAPER IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (ASP)

TABLE 59 NORTH AMERICA SENSITIVITY IS 50NG/ML IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 60 NORTH AMERICA SENSITIVITY IS 50NG/ML IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (UNIT)

TABLE 61 NORTH AMERICA SENSITIVITY IS 50NG/ML IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (ASP)

TABLE 62 NORTH AMERICA SENSITIVITY IS 75NG/ML IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 63 NORTH AMERICA SENSITIVITY IS 75NG/ML IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (UNIT)

TABLE 64 NORTH AMERICA SENSITIVITY IS 75NG/ML IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (ASP)

TABLE 65 NORTH AMERICA REAGENTS IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 66 NORTH AMERICA REAGENTS IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (UNIT)

TABLE 67 NORTH AMERICA REAGENTS IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (ASP)

TABLE 68 NORTH AMERICA FECAL OCCULT BLOOD TESTS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 69 NORTH AMERICA COLORECTAL CANCER SCREENING IN FECAL OCCULT BLOOD TESTS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 70 NORTH AMERICA CONCERN FOR GASTROINTESTINAL BLEEDING IN FECAL OCCULT BLOOD TESTS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 71 NORTH AMERICA POLYPS IN FECAL OCCULT BLOOD TESTS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 72 NORTH AMERICA DIVERTICULOSIS IN FECAL OCCULT BLOOD TESTS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 73 NORTH AMERICA ULCERS IN FECAL OCCULT BLOOD TESTS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 74 NORTH AMERICA HAEMORRHOIDS IN FECAL OCCULT BLOOD TESTS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 75 NORTH AMERICA COLITIS IN FECAL OCCULT BLOOD TESTS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 76 NORTH AMERICA ANEMIA IN FECAL OCCULT BLOOD TESTS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 77 NORTH AMERICA FECAL OCCULT BLOOD TESTS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 78 NORTH AMERICA FECAL OCCULT BLOOD TESTS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 79 U.S. FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 80 U.S. FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (UNIT)

TABLE 81 U.S. FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (ASP)

TABLE 82 U.S. GUAIAC FOB STOOL TEST IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 83 U.S. GUAIAC FOB STOOL TEST IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (UNIT)

TABLE 84 U.S. GUAIAC FOB STOOL TEST IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (ASP)

TABLE 85 U.S. KITS IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 86 U.S. KITS IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (UNIT)

TABLE 87 U.S. KITS IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (ASP)

TABLE 88 U.S. GUAIAC SLIDES IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 89 U.S. GUAIAC SLIDES IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (UNIT)

TABLE 90 U.S. GUAIAC SLIDES IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (ASP)

TABLE 91 U.S. ALPHA GUAIACONIC ACID (GUAIAC) IMPREGNATED PAPER IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 92 U.S. ALPHA GUAIACONIC ACID (GUAIAC) IMPREGNATED PAPER IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (UNIT)

TABLE 93 U.S. ALPHA GUAIACONIC ACID (GUAIAC) IMPREGNATED PAPER IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (ASP)

TABLE 94 U.S. SENSITIVITY IS 50NG/ML IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 95 U.S. SENSITIVITY IS 50NG/ML IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (UNIT)

TABLE 96 U.S. SENSITIVITY IS 50NG/ML IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (ASP)

TABLE 97 U.S. SENSITIVITY IS 75NG/ML IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 98 U.S. SENSITIVITY IS 75NG/ML IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (UNIT)

TABLE 99 U.S. SENSITIVITY IS 75NG/ML IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (ASP)

TABLE 100 U.S. REAGENTS IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 101 U.S. REAGENTS IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (UNIT)

TABLE 102 U.S. REAGENTS IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (ASP)

TABLE 103 U.S. FECAL OCCULT BLOOD TESTS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 104 U.S. COLORECTAL CANCER SCREENING IN FECAL OCCULT BLOOD TESTS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 105 U.S. CONCERN FOR GASTROINTESTINAL BLEEDING IN FECAL OCCULT BLOOD TESTS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 106 U.S. POLYPS IN FECAL OCCULT BLOOD TESTS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 107 U.S. DIVERTICULOSIS IN FECAL OCCULT BLOOD TESTS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 108 U.S. ULCERS IN FECAL OCCULT BLOOD TESTS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 109 U.S. HAEMORRHOIDS IN FECAL OCCULT BLOOD TESTS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 110 U.S. COLITIS IN FECAL OCCULT BLOOD TESTS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 111 U.S. ANEMIA IN FECAL OCCULT BLOOD TESTS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 112 U.S. FECAL OCCULT BLOOD TESTS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 113 U.S. FECAL OCCULT BLOOD TESTS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 114 CANADA FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 115 CANADA FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (UNIT)

TABLE 116 CANADA FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (ASP)

TABLE 117 CANADA GUAIAC FOB STOOL TEST IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 118 CANADA GUAIAC FOB STOOL TEST IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (UNIT)

TABLE 119 CANADA GUAIAC FOB STOOL TEST IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (ASP)

TABLE 120 CANADA KITS IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 121 CANADA KITS IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (UNIT)

TABLE 122 CANADA KITS IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (ASP)

TABLE 123 CANADA GUAIAC SLIDES IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 124 CANADA GUAIAC SLIDES IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (UNIT)

TABLE 125 CANADA GUAIAC SLIDES IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (ASP)

TABLE 126 CANADA ALPHA GUAIACONIC ACID (GUAIAC) IMPREGNATED PAPER IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 127 CANADA ALPHA GUAIACONIC ACID (GUAIAC) IMPREGNATED PAPER IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (UNIT)

TABLE 128 CANADA ALPHA GUAIACONIC ACID (GUAIAC) IMPREGNATED PAPER IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (ASP)

TABLE 129 CANADA SENSITIVITY IS 50NG/ML IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 130 CANADA SENSITIVITY IS 50NG/ML IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (UNIT)

TABLE 131 CANADA SENSITIVITY IS 50NG/ML IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (ASP)

TABLE 132 CANADA SENSITIVITY IS 75NG/ML IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 133 CANADA SENSITIVITY IS 75NG/ML IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (UNIT)

TABLE 134 CANADA SENSITIVITY IS 75NG/ML IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (ASP)

TABLE 135 CANADA REAGENTS IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 136 CANADA REAGENTS IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (UNIT)

TABLE 137 CANADA REAGENTS IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (ASP)

TABLE 138 CANADA FECAL OCCULT BLOOD TESTS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 139 CANADA COLORECTAL CANCER SCREENING IN FECAL OCCULT BLOOD TESTS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 140 CANADA CONCERN FOR GASTROINTESTINAL BLEEDING IN FECAL OCCULT BLOOD TESTS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 141 CANADA POLYPS IN FECAL OCCULT BLOOD TESTS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 142 CANADA DIVERTICULOSIS IN FECAL OCCULT BLOOD TESTS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 143 CANADA ULCERS IN FECAL OCCULT BLOOD TESTS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 144 CANADA HAEMORRHOIDS IN FECAL OCCULT BLOOD TESTS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 145 CANADA COLITIS IN FECAL OCCULT BLOOD TESTS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 146 CANADA ANEMIA IN FECAL OCCULT BLOOD TESTS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 147 CANADA FECAL OCCULT BLOOD TESTS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 148 CANADA FECAL OCCULT BLOOD TESTS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 149 MEXICO FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 150 MEXICO FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (UNIT)

TABLE 151 MEXICO FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (ASP)

TABLE 152 MEXICO GUAIAC FOB STOOL TEST IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 153 MEXICO GUAIAC FOB STOOL TEST IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (UNIT)

TABLE 154 MEXICO GUAIAC FOB STOOL TEST IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (ASP)

TABLE 155 MEXICO KITS IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 156 MEXICO KITS IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (UNIT)

TABLE 157 MEXICO KITS IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (ASP)

TABLE 158 MEXICO GUAIAC SLIDES IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 159 MEXICO GUAIAC SLIDES IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (UNIT)

TABLE 160 MEXICO GUAIAC SLIDES IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (ASP)

TABLE 161 MEXICO ALPHA GUAIACONIC ACID (GUAIAC) IMPREGNATED PAPER IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 162 MEXICO ALPHA GUAIACONIC ACID (GUAIAC) IMPREGNATED PAPER IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (UNIT)

TABLE 163 MEXICO ALPHA GUAIACONIC ACID (GUAIAC) IMPREGNATED PAPER IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (ASP)

TABLE 164 MEXICO SENSITIVITY IS 50NG/ML IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 165 MEXICO SENSITIVITY IS 50NG/ML IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (UNIT)

TABLE 166 MEXICO SENSITIVITY IS 50NG/ML IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (ASP)

TABLE 167 MEXICO SENSITIVITY IS 75NG/ML IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 168 MEXICO SENSITIVITY IS 75NG/ML IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (UNIT)

TABLE 169 MEXICO SENSITIVITY IS 75NG/ML IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (ASP)

TABLE 170 MEXICO REAGENTS IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 171 MEXICO REAGENTS IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (UNIT)

TABLE 172 MEXICO REAGENTS IN FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE, 2021-2030 (ASP)

TABLE 173 MEXICO FECAL OCCULT BLOOD TESTS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 174 MEXICO COLORECTAL CANCER SCREENING IN FECAL OCCULT BLOOD TESTS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 175 MEXICO CONCERN FOR GASTROINTESTINAL BLEEDING IN FECAL OCCULT BLOOD TESTS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 176 MEXICO POLYPS IN FECAL OCCULT BLOOD TESTS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 177 MEXICO DIVERTICULOSIS IN FECAL OCCULT BLOOD TESTS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 178 MEXICO ULCERS IN FECAL OCCULT BLOOD TESTS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 179 MEXICO HAEMORRHOIDS IN FECAL OCCULT BLOOD TESTS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 180 MEXICO COLITIS IN FECAL OCCULT BLOOD TESTS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 181 MEXICO ANEMIA IN FECAL OCCULT BLOOD TESTS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 182 MEXICO FECAL OCCULT BLOOD TESTS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 183 MEXICO FECAL OCCULT BLOOD TESTS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

List of Figure

FIGURE 1 NORTH AMERICA FECAL OCCULT BLOOD TESTSMARKET: SEGMENTATION

FIGURE 2 NORTH AMERICA FECAL OCCULT BLOOD TESTS MARKET: DATA TRIANGULATION

FIGURE 3 NORTH AMERICA FECAL OCCULT BLOOD TESTS MARKET: DROC ANALYSIS

FIGURE 4 NORTH AMERICA FECAL OCCULT BLOOD TESTS MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS

FIGURE 5 NORTH AMERICA FECAL OCCULT BLOOD TESTS MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 NORTH AMERICA FECAL OCCULT BLOOD TESTS MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 NORTH AMERICA FECAL OCCULT BLOOD TESTS MARKET: MARKET APPLICATION COVERAGE GRID

FIGURE 8 NORTH AMERICA FECAL OCCULT BLOOD TESTSMARKET: DBMR MARKET POSITION GRID

FIGURE 9 NORTH AMERICA FECAL OCCULT BLOOD TESTS MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 NORTH AMERICA FECAL OCCULT BLOOD TESTS MARKET: SEGMENTATION

FIGURE 11 RISING CASES OF COLORECTAL CANCER NORTH AMERICALY AND EASY AVAILABILITY OF FECAL OCCULT IMMUNOLOGICAL TEST DEVICES IN ONLINE STORES ARE EXPECTED TO DRIVE THE GROWTH OF THE NORTH AMERICA FECAL OCCULT BLOOD TESTS MARKET FROM 2023 TO 2030

FIGURE 12 THE LATERAL FLOW IMMUNO-FOB, TEST KITS SEGMENT, IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA FECAL OCCULT BLOOD TESTS MARKET IN 2023 & 2030

FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE NORTH AMERICA FECAL OCCULT BLOOD TESTS MARKET

FIGURE 14 NORTH AMERICA FECAL OCCULT BLOOD TESTS MARKET: BY TEST TYPE, 2022

FIGURE 15 NORTH AMERICA FECAL OCCULT BLOOD TESTS MARKET: BY TEST TYPE, 2023-2030 (USD MILLION)

FIGURE 16 NORTH AMERICA FECAL OCCULT BLOOD TESTS MARKET: BY TEST TYPE, CAGR (2023-2030)

FIGURE 17 NORTH AMERICA FECAL OCCULT BLOOD TESTS MARKET: BY TEST TYPE, LIFELINE CURVE

FIGURE 18 NORTH AMERICA FECAL OCCULT BLOOD TESTS MARKET: BY APPLICATION, 2022

FIGURE 19 NORTH AMERICA FECAL OCCULT BLOOD TESTS MARKET: BY APPLICATION, 2023-2030 (USD MILLION)

FIGURE 20 NORTH AMERICA FECAL OCCULT BLOOD TESTS MARKET: BY APPLICATION, CAGR (2023-2030)

FIGURE 21 NORTH AMERICA FECAL OCCULT BLOOD TESTS MARKET: BY APPLICATION, LIFELINE CURVE

FIGURE 22 NORTH AMERICA FECAL OCCULT BLOOD TESTS MARKET: BY END USER, 2022

FIGURE 23 NORTH AMERICA FECAL OCCULT BLOOD TESTS MARKET: BY END USER, 2023-2030 (USD MILLION)

FIGURE 24 NORTH AMERICA FECAL OCCULT BLOOD TESTS MARKET: BY END USER, CAGR (2023-2030)

FIGURE 25 NORTH AMERICA FECAL OCCULT BLOOD TESTS MARKET : BY END USER, LIFELINE CURVE

FIGURE 26 NORTH AMERICA FECAL OCCULT BLOOD TESTS MARKET : BY DISTRIBUTION CHANNEL, 2022

FIGURE 27 NORTH AMERICA FECAL OCCULT BLOOD TESTS MARKET : BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

FIGURE 28 NORTH AMERICA FECAL OCCULT BLOOD TESTS MARKET : BY DISTRIBUTION CHANNEL, CAGR (2023-2030)

FIGURE 29 NORTH AMERICA FECAL OCCULT BLOOD TESTS MARKET : BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 30 NORTH AMERICA FECAL OCCULT BLOOD TESTS MARKET: SNAPSHOT (2022)

FIGURE 31 NORTH AMERICA FECAL OCCULT BLOOD TESTS MARKET: BY COUNTRY (2022)

FIGURE 32 NORTH AMERICA FECAL OCCULT BLOOD TESTS MARKET: BY COUNTRY (2023 & 2030)

FIGURE 33 NORTH AMERICA FECAL OCCULT BLOOD TESTS MARKET: BY COUNTRY (2023 & 2030)

FIGURE 34 NORTH AMERICA FECAL OCCULT BLOOD TESTS MARKET: BY TEST TYPE (2023-2030)

FIGURE 35 NORTH AMERICA FECAL OCCULT BLOOD TESTS MARKET: COMPANY SHARE 2022 (%)

View Detailed Information Right Arrow

منهجية البحث

يتم جمع البيانات وتحليل سنة الأساس باستخدام وحدات جمع البيانات ذات أحجام العينات الكبيرة. تتضمن المرحلة الحصول على معلومات السوق أو البيانات ذات الصلة من خلال مصادر واستراتيجيات مختلفة. تتضمن فحص وتخطيط جميع البيانات المكتسبة من الماضي مسبقًا. كما تتضمن فحص التناقضات في المعلومات التي شوهدت عبر مصادر المعلومات المختلفة. يتم تحليل بيانات السوق وتقديرها باستخدام نماذج إحصائية ومتماسكة للسوق. كما أن تحليل حصة السوق وتحليل الاتجاهات الرئيسية هي عوامل النجاح الرئيسية في تقرير السوق. لمعرفة المزيد، يرجى طلب مكالمة محلل أو إرسال استفسارك.

منهجية البحث الرئيسية التي يستخدمها فريق بحث DBMR هي التثليث البيانات والتي تتضمن استخراج البيانات وتحليل تأثير متغيرات البيانات على السوق والتحقق الأولي (من قبل خبراء الصناعة). تتضمن نماذج البيانات شبكة تحديد موقف البائعين، وتحليل خط زمني للسوق، ونظرة عامة على السوق ودليل، وشبكة تحديد موقف الشركة، وتحليل براءات الاختراع، وتحليل التسعير، وتحليل حصة الشركة في السوق، ومعايير القياس، وتحليل حصة البائعين على المستوى العالمي مقابل الإقليمي. لمعرفة المزيد عن منهجية البحث، أرسل استفسارًا للتحدث إلى خبراء الصناعة لدينا.

التخصيص متاح

تعد Data Bridge Market Research رائدة في مجال البحوث التكوينية المتقدمة. ونحن نفخر بخدمة عملائنا الحاليين والجدد بالبيانات والتحليلات التي تتطابق مع هدفهم. ويمكن تخصيص التقرير ليشمل تحليل اتجاه الأسعار للعلامات التجارية المستهدفة وفهم السوق في بلدان إضافية (اطلب قائمة البلدان)، وبيانات نتائج التجارب السريرية، ومراجعة الأدبيات، وتحليل السوق المجدد وقاعدة المنتج. ويمكن تحليل تحليل السوق للمنافسين المستهدفين من التحليل القائم على التكنولوجيا إلى استراتيجيات محفظة السوق. ويمكننا إضافة عدد كبير من المنافسين الذين تحتاج إلى بيانات عنهم بالتنسيق وأسلوب البيانات الذي تبحث عنه. ويمكن لفريق المحللين لدينا أيضًا تزويدك بالبيانات في ملفات Excel الخام أو جداول البيانات المحورية (كتاب الحقائق) أو مساعدتك في إنشاء عروض تقديمية من مجموعات البيانات المتوفرة في التقرير.

Frequently Asked Questions

The North America Fecal Occult Blood Tests Market is projected to grow at a CAGR of 5.9% during the forecast period by 2030.
The future market value of the North America Fecal Occult Blood Tests Market is expected to reach USD 1,019.00 million by 2030.
The major players in the North America Fecal Occult Blood Tests Market are Biopanda Reagents Ltd, HUMASIS.COM, CTK Biotech, Inc., Biohit Oyj, CERTEST BIOTEC, Alfa Scientific Designs, Inc., Cenogenics Corporation, and Jant Pharmacal Corporation., Quidel Corporation, etc.
The countries covered in the North America Fecal Occult Blood Tests Market are U.S., Canada, and Mexico.